Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Internal Medicine Section Endocrinology, Amsterdam Bone Center, Amsterdam Movement Sciences, the Netherlands.
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology & Nuclear Medicine, the Netherlands.
Bone. 2019 Jul;124:1-6. doi: 10.1016/j.bone.2019.03.009. Epub 2019 Mar 8.
Fibrodysplasia ossificans progressiva (FOP) is a rare, autosomal dominant disorder characterized by heterotopic ossification (HO) in muscles, ligaments and tendons. Flare-ups often precede the formation of HO, resulting in immobilization of joints. Due to progression of the disease without signs of a flare-up, co-existence of a chronic progression of HO has been postulated, but conclusive evidence is lacking. Recently, it has been shown that [F]NaF PET/CT is able to identify early ossifying disease activity during flare-ups. Therefore, the purpose of the present study was to assess whether [F]NaF PET/CT might also be able to identify the possible presence of chronic progressive HO in FOP. A total of thirteen [F]NaF PET/CT scans from five FOP patients were analysed. Scans were acquired over a period of 0.5 to 2 years. Volumes of HO and standardized uptake values (SUV) were obtained based on manual segmentation of CT images. SUV values, defined as the average SUV value of a 1 mL sphere containing the hottest voxel pixels, were obtained. Two out of five patients experienced ≥1 active clinical flare-ups at the time of the [F]NaF PET/CT scan. In addition, in four out of five patients, serial scans showed radiological progression of HO (3 to 8 cm), as assessed by CT volume, in the absence of a clinical flare-up. This volumetric increase was present in 6/47 (12.8%) of identified HO structures and, in all cases, was accompanied by increased [F]NaF uptake, with SUV ranging from 8.4 to 17.9. In conclusion, HO may progress without signs of a flare-up. [F]NaF PET/CT is able to identify these asymptomatic, but progressive HO lesions, thereby demonstrating the presence of chronic activity in FOP. Consequently, future drugs should not only target new HO formation, but also this chronic HO progression.
进行性骨化性纤维发育不良(FOP)是一种罕见的常染色体显性遗传病,其特征是肌肉、韧带和肌腱的异位骨化(HO)。发作通常先于 HO 的形成,导致关节固定。由于疾病的进展没有发作的迹象,因此推测存在 HO 的慢性进展,但缺乏确凿的证据。最近,已经表明 [F]NaF PET/CT 能够在发作期间识别早期的成骨疾病活动。因此,本研究的目的是评估 [F]NaF PET/CT 是否也能够识别 FOP 中可能存在的慢性进行性 HO。分析了 5 名 FOP 患者的 13 次 [F]NaF PET/CT 扫描。扫描时间为 0.5 至 2 年。HO 和标准化摄取值(SUV)的体积是基于 CT 图像的手动分割获得的。SUV 值定义为包含最热像素的 1ml 球体的平均 SUV 值。在进行 [F]NaF PET/CT 扫描时,有 2 名患者经历了≥1 次活跃的临床发作。此外,在 5 名患者中有 4 名患者的连续扫描显示 HO(3 至 8cm)的放射学进展,这是通过 CT 体积评估的,而没有临床发作。这种体积增加存在于 47 个 HO 结构中的 6 个(12.8%),并且在所有情况下,都伴有 [F]NaF 摄取的增加,SUV 范围为 8.4 至 17.9。总之,HO 可能在没有发作的情况下进展。[F]NaF PET/CT 能够识别这些无症状但进行性的 HO 病变,从而证明 FOP 存在慢性活动。因此,未来的药物不仅应针对新的 HO 形成,还应针对这种慢性 HO 进展。